Interview with Ajit Kamath, Chairman & Managing Director, Arch Pharmalabs
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Address: 541-A, Arch House, Marol Maroshi Road,
Andheri (E), Mumbai – 400 059, India
Tel: 91-22-33089200/33089400
Web: http://www.archpharmalabs.com/index.asp
We are a pharmaceutical company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. We have evolved our business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to our offerings, which has significant potential for the growth of our business.
Lipid Lowering Agent
Calcium Channel Blocker
Anti Platelet Agent
Anti hypertensive
Anti anginal
Anti Asthmatic
Anti Histamine
Anti Diabetic
Anti Protozoal
Anti fungal
Oncology
Anti emetic
Proton pump inhibitor
Expectorant
Decongestant
Anti Depressant
Anti Convulsant
Psychostimulant
Hypnotic
Anti parkinsonian
Anti Retroviral
Anti gout
Analgesic
We have evolved to include Contract Research and Manufacturing Services as our growing business vertical. We have developed capabilities to provide a wide range of CRAMS starting from route selection / process development / optimization, analytical development, stability studies, safety studies, scale-up to technology transfer / clinical-trial manufacturing to commercial manufacturing to suit US / EU regulatory requirements. We can cost-effectively manage several complex reactions at various scales of operation, ranging from a few grams to several tonnes. For instance, we, using a proprietary bio-catalytic/ enzymatic technology availed by us, have developed innovative route for the manufacturing of key advanced intermediates.
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus…
The IDMA’s Daara Patel outlines the association’s role in representing the diverse voices of the Indian pharmaceutical sector, advocating for manufacturers of all sizes. He explores the challenges and initiatives…
Indian pharma companies have been building a broader presence in LatAm markets over the past two decades. With well-established trade relations already in place, the region offers a series of unique…
A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory;…
Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and…
The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and…
The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA…
The latest news from the Indian pharma sector, including the potential for greater numbers of exports and better market access to the UK under a proposed free trade agreement, yet…
As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality…
Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA…
Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework. …
The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to…
See our Cookie Privacy Policy Here
